summari schedul report result
estim total sale organ ep similar
consensu respect expect
report least in-lin assum margin upsid pharma
off-set addit fx headwind expect materi chang
guidanc potenti gener zytiga
competit increment fx headwind im analysi
suggest potenti modest upsid us
recent nielsen trend impli growth us consum
consist view updat model
diabet divestitur assum off-set ep dilut
addit headwind includ fx asp divestitur new
generic/biosimilar competit note summar im
trend jnj key us drug
updat model diabet divestitur lifescan
divestitur complet updat model reflect
impact start assum abl off-set
much estim annual ep dilut associ
deal recogn gain sale
asset alreadi incorpor current guidanc
modest potenti upsid us pharma
assum growth deceler larg due tougher yr/yr comp
base im data rais us forecast stelara
zytiga lower estim remicad note
potenti modest addit upsid product like xarelto
assum slight growth acceler ww consum sale
babi care relaunch
medic devic see slight growth acceler
believ guidanc unlik materi chang
estim sale consensu
organ growth within guidanc growth
ep estim consensu
within guidanc rang expect
materi chang guidanc likelihood us
gener zytiga competit view increment fx
headwind although jnj guidanc assum gener zytiga
believ compani absorb impact given late
year
potenti headwind yet give
guidanc see sever potenti headwind could depress
growth next year potenti headwind would highlight includ fx
dilut asp diabet divestitur us
pharmaceut sale growth depress ep growth
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
compani data secur llc estim reuter
us pharma consum like in-lin expect report result
estim total sale organ ep similar consensu
respect expect report least in-lin assum margin upsid
pharma off-set addit fx headwind forecast assum fx headwind
wors time call pharma estim organ sale growth vs
growth deceler larg reflect tougher yr/yr comp
growth vs analysi im data point like upsid us
stelara zytiga sale downsid remicad sale updat forecast
product extrapol im sale also suggest potenti modest upsid us product like xarelto
opsumit chang estim due uncertainti impact
rebating/discount patient assist program model essenti stabl organ growth
medic devic vs consum estim organ growth
in-lin adjust us babi destock transit strike brazil analysi
nielsen data point growth us consum consist model
updat us pharmaceut sale forecast base im sale analysi im data
jnj key us drug suggest us pharmaceut sale could modestli exceed expect
figur base analysi rais us sale forecast stelara zytiga
lower us sale estim remicad im data also point potenti
upsid sever drug like xarelto key pah pulmonari arteri hypertens drug
howev chang estim product due uncertainti impact
rebating/discount patient assist program estim us pharmaceut sale
yr/yr growth deceler organ growth monthli product tracker
detail start page
price increas rais price wholesal acquisit cost across much us drug
portfolio saw price increas price increas rang
darzalex zytiga estim averag price increas jnj top us
drug account us pharma sale given current environ anticip
limit addit price increas rest net basi adjust discounts/fe
price declin nearli jnj us pharmaceut busi first declin last year
averag manag emphas volum rather price
key driver strong sale growth busi
assum rel stabl consum sale growth report world-wide consum sale
organ growth adjust babi destock transit strike brazil
improv growth due easier comp resolv hurrican maria-rel suppli
disrupt jnj us consum busi analysi aggreg nielsen data
suggest sale growth could acceler consist estim
figur aggreg nielsen data appear trend direct in-lin report us consum
compani report secur llc estim organ growth adjust fx acquisitions/divestitur sell day prior price adjust pharma venezuela anima exit pharma overal growth adjust remicad rebat ex-adjust organ growth pharma overal cardiovascular cerenovu neurovascular intervent solut start diabet adjust anima exit impact amo acqusit includ ex-fx growth rate atln acquisit includ ex-fx growth rate key busi segmentsex-fx growthorgan growth johnson johnson
sale organ growth time figur babi destock ahead relaunch hurt us
consum sale believ impact could start revers assum ou
consum sale growth flattish due tougher comp world-wide basi forecast consum
sale organ growth includ us sale growth
nielsen sale base aggreg data
nielsen sale base aggreg data
estim fx margin wors estim fx headwind
slightli wors estim time jnj report estim fx drag
bottom-lin remain thu manag full year estim fx
tailwind lower jnj guidanc suggest ep impact like coupl
penni guidanc believ abl absorb impact within
current guidanc updat model increas fx headwind assum
materi ep impact
expect guidanc remain larg intact guid organ sale growth
report sale ep may narrow guidanc
rang one quarter remain anticip materi chang sever reason
alreadi rais organ sale growth outlook total two consecut quarter
current guidanc contempl us gener zytiga competit believ like
manag prior comment suggest absorb impact gener competit
rel late year stay expir near end octob
forecast like consensu alreadi account gener zytiga competit stay
end addit believ fx tailwind like lower vs guidanc ep impact
thu cap potenti ep upsid forecast organ sale growth ep
summari key headwind see like gener competit zytiga
tracleer key increment headwind next year togeth product account
estim ww pharmaceut revenu ww total sale also expect
increment biosimilar remicad impact potenti biosimilar procrit competit expect
headwind depress jnj sale growth estim next year
deceler estim growth still ahead consensu median sale growth
large-cap pharma peer medic devic see ep dilut divestitur diabet
estim asp estim headwind bottom-lin addit
note fx repres estim headwind top-lin growth translat
ep dilut math
expect tri off-set mani headwind incom gain sale asp
larger med-tech acquisit see note think med-tech turn sun date
detail possibl addit share repurchas overal estim total sale ex-
diabet consensu organ sale growth ep
consensu below-consensu sale estim like reflect remov diabet revenu
model consensu forecast may fulli updat reflect close divestitur
lower us remicad sale estim base im trend lower us
remicad ex-export sale forecast yr/yr declin repres
deceler report sale declin ex-reb adjust lower
estim base im analysi impli us remicad sale may closer
use recent histor ratio report sale account two-third extrapol im
sale extrapol im sale show declin vs declin
biosimilar remicad continu ramp slowli im sale show biosimilar remicad ramp
remain slow total sale increas juli august figur
entri second biosimilar year ago yet acceler rate biosimilar penetr
trail averag remicad im sale remain differ report
im sale widen past month suggest increas rebat discount
accord biosimilar sale mostli inflectra doubl howev big rebat hurdl
remain allud regulatori help acceler adopt biosimilar patent litig
anti-competit lawsuit still on-going
im data suggest us darzalex sale larg in-lin forecast model
us darzalex sale grow yr/yr forecast slightli extrapol im sale
suggest report sale in-lin perhap slightli estim
key catalyst darzalex maia data front-lin use still expect
approv like longer term on-going phase studi subq formul significantli
reduc infus time expand patient access therebi help maintain darzalex growth
momentum accord brandimpact darzalex held share mm market august
novemb drug first approv use figur line
darzalex maintain lead share august figur darzalex held overal market
share survey despit share front-lin use expect darzalex penetr
line continu rise anticip approv expect help drive overal share gain
impli end-us sale yr/yr appear direct consist
extrapol im sale howev differ report im sale
widen recent quarter suggest discounting/reb may increas thu
ratio reported/im sale may shift rx perspect roll
imbruvica volum grew weekli averag figur pipelin phase
studi imbruvica paclitaxel/gemcitabin pancreat cancer report year-end
howev believ hurdl high assign low probabl success phase
imbruvica mono- combo therapi data differ patient popul watch wait patient
expect emerg reinforc drug benefit front-lin use
imbruvica forecast in-lin guidanc partnership book us
sale book ou sale two split global profit base abbv guidanc us
imbruvica sale impli us revenu vs estim
guid ww imbruvica revenu suggest ou revenu
impli end-us sale in-lin estim call note
imbruvica continu clear leader cll momentum continu base grow
evid drug strong efficaci across multipl indic
invokana/invokamet rx volum share continu fall forecast us invokana sale
mm yr/yr declin seem reason base extrapol im sale
reported/im sale ratio howev reported/im sale ratio declin recent quarter
past year ratio fell report us invokana sale could fall short
expect look monthli data invokana franchis volum fell yr/yr jul/aug
compar declin figur weekli im data first three week septemb show
consist trend volum declin yr/yr figur
next catalyst invokana fda approv canvas/r data file octob
fda extend review period octob recal invokana sale sag
sinc canvas/canvas-r outcom data show invokana effect
reduc cardiovascular risk led significantli higher rate amput fractur
expect present data credenc renal outcom trial stop earli base
interim analysi suggest posit efficaci howev bigger unknown credenc safeti
data clean safeti profil credenc may encourag fda consid remov black box
warn invokana labl may help turnaround invokana sale time diabet
meet june present data real-world analysi suggest increas risk
below-the-kne lower extrem amput invokana vs diabet
drug unclear slightli slower yr/yr rx volum declin recent month reflect encourag
invokana/invokamet share within class continu fall august invokana/invokamet
nrx share fell may januari comparis azn farxiga/xiguo
xr share remain stabl around ytd bi/lli jardianc franchis share climb
januari august figur jardianc mark share dobul past
two year driven posit data label updat base empa-reg outcom trial
show drug lower cardiovascular risk increas amputation/fractur risk growth
overal categori slow jan aug/sep
rais us zytiga sale estim continu assum gener competit
increas us zytiga sale estim yr/yr base
extrapol im sale zytiga growth momentum continu driven posit latitud data
june show drug significantli improv surviv patient hormone-nav
prostat cancer monthli zytiga rx volum growth averag nearli ytd august
compar mostli declin rx volum pre-latitud figur zytiga im sale also shown
strong growth vs flattish low-singl digit growth prior latitud figur
continu expect gener zytiga competit us start late octob
stay expir base consult review post-trial brief relat patent
believ gener challeng like prevail patent case trial judg indic decis
made end although guidanc assum gener entri
model believ consensu forecast larg take gener competiton account alreadi
erleada strong start help overal prostat cancer pc franchis
possibl gener zytiga competit later could see signific pressur jnj pc
franchis current estim us pc sale fall quarterli sale
base week erleada rx data far note monthli volum doubl
past three month monthli nrx volum remain rel flat estim us erleada sale
compar
potenti upsid xarelto sale estim compass approv pend forecast
xarelto sale grow yr/yr seem conserv vs extrapol im sale
better believ rebating/discount continu play import role
competit market could make histor reported/im sale ratio less reliabl monthli trx nrx
volum show solid yr/yr growth jul/aug consist ytd trend figur
overal novel oral anticoagul noac market rx growth low-
august eliqui maintain lead among noac share m/m follow
xarelto share m/m past year xarelto lost share eliqui
gain share figur noac account oral anticoagul nrx vs
end xarelto launch figur
next key catalyst xarelto fda approv compass data expect year-end
file compass data late cad/pad coronari arteri disease/peripher arteri diseas
compass expect expand xarelto address patient popul help improv
growth share fail marin medic ill commander-hf heart failur studi
repres modest setback outlook xarelto growth rebound view
us invega sustenna/trinza sale could margin exceed expect estim
us sale yr/yr growth extrapol im sale suggest report sale could
margin higher im sale jnj long-act inject atyp laia franchis sustenna trinza
risperd consta grew jul/aug larg consist growth trend figur
steadi growth larg reflect continu mid-teen growth sustenna trinza partli off-set
continu mid-singl digit sale declin consta estim trinza account
franchis sale franchis growth base im sale us laia market
maintain sizeabl lead franchis nrx market share past
month ostuka abilifi maintena hold share yr/yr aristada share
rais us stelara sale forecast base im trend estim us stelara sale
yr/yr growth appear conserv compar extrapol im sale suggest
report sale exceed recent histori point fairli stabl reported/im sale ratio
suggest im sale trend may reason indic report sale
increas us stelara sale forecast growth stelara im sale grew
jul/aug ytd growth figur trx volum specialti suggest crohn
remain key growth driver monthli written gastroenterolog specialist stelara
essenti doubl past year rheumatologist
dermatologist stelara pace volum declin among
dermatologist consist note volum rheumatologist revers cours
low-singl digit growth earlier year pipelin perspect plan file stelara
approv ulcer coliti us ou
us tremfya sale could better expect forecast us tremfya sale
compar averag quarterli sale extrapol im sale suggest report sale
exceed year market tremfya im sale annual
nearli base august data comparison nv cosentyx lli taltz sale
annual first year market current cosentyx im sale annual
taltz im sale annual weekli tremfya volum appear track in-lin
stelara remain behind cosentyx taltz time post-launch figur im like
continu underestim true tremfya uptak due exclus free sampl data
accord recent pharma call tremfya see particularli strong uptak among
dermatologist outpac new-to-brand share continu view tremfya
import growth driver jnj pharma franchis although expect drug cannib stelara
sale among dermatologist time
sale yr/yr growth seem reason base extrapol im sale
suggest report sale jul/aug simponi im sale flattish yr/yr aria im
sale grew togeth drive franchis growth repres deceler
growth growth note im sale growth fairli steadi
ytd simponi im sale deceler cours figur
us pah sale could exceed estim reported/im sale correl
consist anniversari atln acquisit continu track im sale trend
top three atln drug opsumit tracleer uptravi figur togeth account
total us pah peripher arteri hypertens sale caveat
consist ratio report im sale past four quarter part due impact patient
assist program make extrapol im sale less meaning estim report sale
aggreg see potenti upsid us pah sale estim
estim us opsumit sale yr/yr growth compar extrapol im data
suggest sale may closer im sale growth estim us tracleer sale
yr/yr declin tracleer im sale increas q/q assum
report us tracleer sale also increas sequenti sale exceed vs
estim vs report sale yet see fda approv
gener tracleer continu expect gener competit uptravi estim us
sale yr/yr growth extrapol im data suggest sale could margin
higher im sale growth patient assist program growth headwind pah
product impact abat somewhat reduc impact patient assist could make
im sale use gaug report sale futur
compris mostli pfe/celltrion inflectra
figur darzalex hold posit line multipl myeloma market
reportedim estim us split im health incorpor nation sale perspect compani report secur llc estim sale estim base commentari im data forecast us imbruvica sale assum record end-us sale report consist third month perform prior quarter assum septemb im sale repres im sale remicadebiosimilar estim uniqu patientsal otherrevlimidvelcadedarzalexkyprolispomalystfarydakninlaroempl medic technolog
figur darzalex maintain lead line multipl myeloma market
follow chang imbruvica ndc nation drug code im report doubl count rx
one distributor late march spike nrx volum april late may suggest us
report issu persist im current look data
estim uniqu patientsal rxtrxnrxfeb cll approvedmar front-lin cll approvedjul r/r cll label expans includ mutat jan waldenstrm macroglobulinemia approvedaug graft-vs-host-diseas cgvhd growthmonthli trxtrx volumetrx growth johnson johnson
figur invokana franchis continu lose share
figur zytiga erleada monthli volum growth
rx y/i present canva data ada meet -posit efficaci safeti trade-off strengthen warn risk acut kidney add black box warn leg foot amput market share invokana invokamet jardianc synjardi glyxambi azn farxiga xigduo growthmonthli trxtrx growthtrx volumezytiga latitud data jun medic technolog
new oral anticoagul includ pradaxa xarelto eliqui savaysa
 nrxnrxoral anticoagulantsnew oral anticoagul new oral anticoagul xarelto spaf approvedeliqui spaf approvedeliqui dvt prevent approvedsavaysa spaf approvedeliqui dvt treatment approvedxarelto dvt treatment growthim sale sustenna trinza consta sale yoy im sale growthsustenna launch aug launch jun market sharealk aristadaotsuka abilifi maintenajnj sinvega sustenna trinza risperd consta medic technolog
figur stelara maintain robust im sale growth trend
figur atln opsumit im sale growth continu
figur atln tracleer im sale continu declin
figur atln uptravi im sale remain solid launch trajectori
analysi independ arriv secur llc basi data
inform im respons relianc recipi either data analys
potenti approv us/eudarzalex alcyon front-lin multipl myeloma nontranspl us mayfront-lin multipl myeloma nontranspl eu augxareltocad/pad us apalutamid prostat cancer us febsymtuza darunavir str d/c/f/taf hiv us julzytigahormone-nav metastat prostat cancer us febjuluca edur dolutegravir fdc viiv hiv mainten treatment eu mayinvokanacanvas/canvas-r-cv outcom us review extend month imbruvica combo w/ rituximabtn wm us aug prioriti review plan submiss us/euesketaminetreat resist depress trd sep us oct eu xarelto line extensionschf us/eu command hf studi fail imbruvica line extensionscombo w/ gazyva obinutuzumab cll front-lin mainten us larg cell lymphoma us/eu cancer us sepopsumitcteph chronic thromboembol pulmonari hypertens us apr /eu sep erleada zytigachemo nave prostat cancer aci prostat cancer eu hormone-sensit prostat cancer titan clinic data presentationserleadaspartan feb genitourinari cancer symposium pre-metastat prostat may trd may ascp stelaraunifi ulcer coliti imbruvicaillumin frontlin cll gazyva combo may phoenix dlbcl frontlin studi fail innov combo w/ rituximab jun darzalexmaia w/ revlimid dex front-lin mm explor program command hf chf marin medic ill pt aug esc studi failedsymtuzahiv id week oct tremfya self dose devic orion dlbl relaps captiv frontlin cll combo w/ venclexta jun hiv vaccineasc travers hiv darzalexphas griffin front-lin mm feb genitourinari cancer symposium bladder cancer phase johnson johnson
price target nc
price target impli cash ep base sum-of-the-
part analysi risk includ delay pipelin product unexpect delay deal integr
unexpect deterior industri
expect overal growth improv multipl tailwind recent acquisit start
contribut organ
johnson johnson world comprehens broadli base healthcar compani
consum pharmaceut medic devic market medic devic segment consist primarili
product cardiovascular orthoped surgic vision compani report sale
year-over-year organ basi
